Payment overview · 2025
General Payments
$210.65
11 reported records · 7 companies
Healthcare provider profile · identity verified
Yuri Talalaev, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKESIDE, AZ · NPI 1548372089
Verified facts
What the public records show
CMS Open Payments records show Yuri Talalaev, MD received $210.65 in general payments during 2025 across 11 reported records.
GlaxoSmithKline, LLC. accounted for 45.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.97 | 45.6% | 5 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $23.83 | 11.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.00 | 10.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.10 | 9.5% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $17.53 | 8.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.14 | 7.7% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $16.08 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $210.65 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $57.84 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.13 | 2 | 2025 |
Source payment records
|
|||||
| SUPARTZ FX SODIUM HYALURONATE Normalized: supartz fx sodium hyaluronate |
Device | Bioventus LLC | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 514 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 105 |
| Lisinopril | Lisinopril | 223 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 48 |
| Montelukast Sodium | Montelukast Sodium | 168 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 150 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 37 |
| Losartan Potassium | Losartan Potassium | 130 | 42 |
| Gabapentin | Gabapentin | 123 | 43 |
| Metformin Hcl | Metformin Hcl | 121 | 39 |
| Simvastatin | Simvastatin | 115 | 37 |
| Omeprazole | Omeprazole | 114 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 38 |
| Trazodone Hcl | Trazodone Hcl | 110 | 37 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | 17 |
| Tramadol Hcl | Tramadol Hcl | 90 | 43 |
| Meloxicam | Meloxicam | 89 | 28 |
| Liothyronine Sodium | Liothyronine Sodium | 87 | 35 |
| Furosemide | Furosemide | 78 | 35 |
| Allopurinol | Allopurinol | 74 | 26 |
| Eliquis | Apixaban | 65 | 22 |
| Methylprednisolone | Methylprednisolone | 65 | 47 |
| Glimepiride | Glimepiride | 64 | 18 |
| Sertraline Hcl | Sertraline Hcl | 64 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 31 |
| Finasteride | Finasteride | 59 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 16 |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 16 |
| Lorazepam | Lorazepam | 47 | 11 |
| Carvedilol | Carvedilol | 46 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 13 |
| Methocarbamol | Methocarbamol | 43 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Nystatin | Nystatin | 41 | 18 |
| Lovastatin | Lovastatin | 36 | 11 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 12 |
| Spironolactone | Spironolactone | 34 | 13 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Baclofen | Baclofen | 33 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Famotidine | Famotidine | 29 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Prednisone | Prednisone | 24 | 13 |
| Alprazolam | Alprazolam | 23 | 14 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Valsartan | Valsartan | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Ozempic | Semaglutide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Sumatriptan | Sumatriptan | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $210.65 · 11 records | GlaxoSmithKline, LLC. | BREZTRI, COLLAGENASE SANTYL, KISUNLA, REXULTI, SHINGRIX, SUPARTZ FX SODIUM HYALURONATE, Senza, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error